What caused the intraday move in OBSN.SW stock today?

The intraday fall to CHF 0.0012 was driven by heavy trading volume (2,351,202 shares) and investor re-rating on clinical timelines and funding uncertainty. Small-cap biotech stocks like ObsEva react strongly to program updates and liquidity signals.

What is Meyka AI’s view on OBSN.SW stock?

Meyka AI rates OBSN.SW at **62.57** (Grade B, Suggestion: HOLD). The grade weighs sector comparison, financial growth, forecasts, key metrics and analyst views. This is informational and not financial advice.

What price target or forecast exists for OBSN.SW stock?

Meyka AI's forecast model projects **CHF 0.0080** for OBSN.SW over 12 months, implying roughly **566.67%** upside from today’s CHF 0.0012. Forecasts are model-based projections and not guarantees.

How liquid is OBSN.SW stock for intraday trading on SIX?

Liquidity can be episodic. Average volume is **675,842** but today’s volume was **2,351,202**, giving a relative volume of **3.48**. Expect wider spreads and higher volatility on low-priced biotechnology names.

CH Stocks

OBSN.SW stock CHF 0.0012 on SIX intraday 04 Mar 2026: heavy volume signals repositioning

ByHuzaifa Zahoor March 4, 2026

OBSN.SW stock traded at CHF 0.0012 on SIX intraday on 04 Mar 2026 after a sharp drop from the previous close of CHF 0.0052. The move is accompanied by 2,351,202 shares traded, more than three times average volume, placing ObsEva S.A. among the Swiss market’s most active names. This intraday note connects the volume spike to recent clinical and funding context and flags valuation, liquidity and short-term technical levels for traders and investors tracking biotechnology exposure in Switzerland.